Ticarcillin/clavulanic acid
| Combination of | |
|---|---|
| Ticarcillin | β-lactam antibiotic |
| Clavulanic acid | β-lactamase inhibitor |
| Clinical data | |
| Trade names | Timentin |
| Routes of administration | Injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
Ticarcillin/clavulanic acid, or co-ticarclav, is a combination antibiotic consisting of ticarcillin, a β-lactam antibiotic, and clavulanic acid, a β-lactamase inhibitor. This combination results in an antibiotic with an increased spectrum of action and restored efficacy against ticarcillin-resistant bacteria that produce certain β-lactamases.[1][2]
References
[edit]- ^ Sutherland R (June 1991). "Beta-lactamase inhibitors and reversal of antibiotic resistance". Trends in Pharmacological Sciences. 12 (6): 227–232. doi:10.1016/0165-6147(91)90557-9. PMID 2048218.
- ^ GlaxoSmithKline. Date of Revision: February 7, 2014
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by adding missing information. |